Jordanian Pharmaceutical Manufacturing Co PSC

JPM maintains a capital structure with a debt-to-equity ratio of 0.67, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.13, suggesting limited short-term liquidity cushion. Free cash flow of 4,458,840 JOD supports operational flexibility, though cash and equivalents are minimal at 12,500 JOD. Profitability metrics show a return on equity of 16.8% and return on assets of 8.7%, both exceeding the typical thresholds for pharmaceutical firms, indicating strong capital efficiency. Operating income of 4,401,640 JOD and net income of 4,128,390 JOD reflect solid earnings performance relative to revenue of 23,562,080 JOD. JPM's revenue is concentrated in its core pharmaceutical and medical appliance segments, with no disclosed geographic diversification beyond Jordan. Subsidiaries include wholly owned Dallas Company for Natural Products and Sawagh Pharmaceutical and Food Industries Company, as well as 99.66%-owned Algerian Jordanian Pharmaceutical Company. Outlook for the current fiscal year shows a stable revenue trajectory, though no specific growth rate is provided. The company's capital expenditure of -619,840 JOD suggests a reduction in investment activity, which may reflect a focus on cost optimization. Risk factors include a medium liquidity risk and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted measures. No recent events or filings are disclosed that would materially alter the company's risk profile. Recent financial filings and transcripts are not provided in the input data, so no specific events can be cited for the period under review.